All articles tagged with #obicetrapib
A new experimental drug, Obicetrapib, has shown promise in reducing LDL cholesterol and lipoprotein(a) levels in a Phase 3 trial, potentially offering a convenient once-daily option to lower heart attack and stroke risk, though further research is needed to confirm its impact on actual cardiovascular events.
A new experimental daily pill called Obicetrapib has shown promise in reducing LDL cholesterol and lipoprotein(a) levels by over 30% in a Phase 3 trial, potentially offering a more convenient option for lowering heart attack and stroke risk, though further research is needed to confirm its impact on actual cardiovascular events.
A new pill called Obicetrapib significantly lowers 'bad' LDL cholesterol and lipoprotein(a) levels in just 12 weeks, offering a promising treatment for high-risk heart patients, with results showing over 30% reduction and good tolerability.